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The medicinal product “Zorex” is currently nationally
authorized in the Russian Federation. It contains unitiol
and calcium pantothenate as active substances. Accord-
ing to the instruction for use it should be administered
in a dosage of one capsule whereupon alcohol drinking
to prevent the hangover or 1-2 times a day to treat the
withdrawal syndrome. For the year 2013, 18 patients
presented in our clinic with allergic reactions for the
drug. Patients: 12 women and 6 men, 21 to 37 years old
(mean age ± 28). In 16 patients such an event took
place not for the first time: in 9 patients the reaction
has developed for the second time, in 5 patients for the
third, and in one woman for the fourth time. Clinical
manifestations: in all patients symptoms have been
developed after the second or third administration of
the drug. All patients noted the febrile chill and the
fever coming, the asthenic syndrome and in 16% of
cases the large joints arthralgia at the first day where-
upon the drug administration. At the end of the day, an
itching skin rash appeared on the back or (less often) on
the palmar surface of hand, as well as shoulders and
armpit areas, buttocks and hip’s internal surfaces, para-
orbital or peroral areas being its the most common
sites. The elements of eruption were rose-to-red spots.
88% of patients had lesions of mouth and lips mucous:
small bubbles with serous contents getting opened
exposing an erosion surface, painful; in some patients
aphtae in the mouth cavity emerged interfering with eat-
ing and causing marked discomfort to patients. 33% of
patients had vesicles on eyelids but with no lesions in
conjunctive. Laboratory tests revealed leukocytosis (± 15
* 109/L), and increased C reactive protein (± 20 mg/L)
levels in all patients. Distinction for the condition is the
regression of primary elements: at the second or the
third day initial spots went to purple-bluish tint, and
then the area remained persistently hyperpigmented.
The hyperpigmentation persists one to two weeks after
the first event. After the following events period of life
of the focus is prolonged, and they persist for one-to-
three months. One patient after the 4th event had a
stable low-grade pigmentation. With each subsequent
administration of the drug rash elements arose in place
of previous eruptions, as well as a number of new ones
appeared. Overall severity of symptoms also increases
with repeating drug administration. All treated patients
had similar clinical symptoms specific to the hypersensi-
tivity reaction to the medicinal drug “Zorex”.
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